REVIEW

Recent advances in understanding lipodystrophy: a focus on lipodystrophy-associated cardiovascular disease and potential effects of leptin therapy on cardiovascular function [version 1; peer review: 3 approved]

Thiago Bruder-Nascimento^{1,2}, Taylor C. Kress¹, Eric J. Belin de Chantemele ^{1,3}

¹Vascular Biology Center, Medical College of Georgia at Augusta University, Augusta, GA, USA

²Department of Pediatrics, Division of Endocrinology, University of Pittsburgh, Pittsburgh, PA, USA

³Department of Medicine, Section of Cardiology, Medical College of Georgia at Augusta University, Augusta, GA, USA

V1 First published: 16 Oct 2019, 8(F1000 Faculty Rev):1756
<https://doi.org/10.12688/f1000research.20150.1>

Latest published: 16 Oct 2019, 8(F1000 Faculty Rev):1756
<https://doi.org/10.12688/f1000research.20150.1>

Abstract

Lipodystrophy is a disease characterized by a partial or total absence of adipose tissue leading to severe metabolic derangements including marked insulin resistance, type 2 diabetes, hypertriglyceridemia, and steatohepatitis. Lipodystrophy is also a source of major cardiovascular disorders which, in addition to hepatic failure and infection, contribute to a significant reduction in life expectancy. Metreleptin, the synthetic analog of the adipocyte-derived hormone leptin and current therapy of choice for patients with lipodystrophy, successfully improves metabolic function. However, while leptin has been associated with hypertension, vascular diseases, and inflammation in the context of obesity, it remains unknown whether its daily administration could further impair cardiovascular function in patients with lipodystrophy. The goal of this short review is to describe the cardiovascular phenotype of patients with lipodystrophy, speculate on the etiology of the disorders, and discuss how the use of murine models of lipodystrophy could be beneficial to address the question of the contribution of leptin to lipodystrophy-associated cardiovascular disease.

Keywords

lipodystrophy, cardiovascular disease, metreleptin, cardiomyopathy, hypertension

Open Peer Review

Approval Status

	1	2	3
version 1
16 Oct 2019			

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Jussara do Carmo**, University of Mississippi Medical Center, Mississippi, USA
2. **Frederique Yiannikouris**, University of Kentucky, Lexington, USA
3. **Xavier Prieur**, L'Institut du Thorax, INSERM, CNRS, Université de Nantes, Nantes, France

Any comments on the article can be found at the end of the article.

Corresponding author: Eric J. Belin de Chantemele (ebelindechanteme@augusta.edu)

Author roles: **Bruder-Nascimento T:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Kress TC:** Writing – Original Draft Preparation; **Belin de Chantemele EJ:** Conceptualization, Funding Acquisition, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by an Established Investigator Award from the American Heart Association (19EIA34760167, to EB), a K99/R00 (1K99HL140139-01A1 and 4R00HL140139-03 to TBN) and R01s (1R01HL130301-01; 1R01HL147639-01A1 to EB) from the National Heart, Lung, and Blood Institute (NHLBI).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2019 Bruder-Nascimento T *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Bruder-Nascimento T, Kress TC and Belin de Chantemele EJ. **Recent advances in understanding lipodystrophy: a focus on lipodystrophy-associated cardiovascular disease and potential effects of leptin therapy on cardiovascular function [version 1; peer review: 3 approved]** F1000Research 2019, 8(F1000 Faculty Rev):1756 <https://doi.org/10.12688/f1000research.20150.1>

First published: 16 Oct 2019, 8(F1000 Faculty Rev):1756 <https://doi.org/10.12688/f1000research.20150.1>

Introduction

Lipodystrophy is a group of clinically heterogeneous diseases characterized by either complete or partial absence of adipose tissue which may occur in conjunction with adipose mass redistribution and can be of either congenital or acquired origin¹. While inherited forms of generalized or partial lipodystrophies are exceedingly rare (1 in 10 million and 1 in 1 million, respectively)² and mainly caused by autosomal recessive mutations of the *AGPAT2*, Berardinelli-Seip congenital lipodystrophy 2 (*BSCL2*), caveolin 1 (*CAVI*), *PTRF* genes^{2–12} or lamin A/C gene¹³, acquired forms of lipodystrophy, on the other hand, have a relatively higher prevalence with an estimated number of 100,000 patients in the United States. Autoimmune disorders and medications including highly active antiretroviral therapy in HIV-infected patients are the leading causes of acquired generalized and partial lipodystrophy^{5,14–16}.

Regardless of the origin of the disease, patients with lipodystrophy share common metabolic abnormalities, which include marked insulin resistance, diabetes mellitus, and hypertriglyceridemia, the severity of which is typically related to the degree of fat loss¹. Metabolic derangements associated with lipodystrophy develop early in life and predispose patients to pancreatitis, non-alcoholic steatohepatitis (NASH), and hepatic failure^{2,5,6,17–20}, the latter being the first cause of morbidity and mortality and of substantial reduction in lifespan (of approximately 30 years) in patients with lipodystrophy²¹. Although less studied and described, cardiovascular disorders including hypertrophic cardiomyopathy, hypertension, and atherosclerosis are also highly prevalent in lipodystrophic patients and additional major contributors to their shortened lifespan²¹.

A key feature of lipodystrophy is a drastic reduction in the levels of adipocyte-derived hormones including leptin, which is a major regulator of appetite, insulin sensitivity, and liver function^{22–26}. Strong basic science and clinical evidence have demonstrated that daily supplementation with leptin in rodent models of lipodystrophy and patients with lipodystrophy restores appetite, glycemia, and hepatic and renal function^{7,16,18,19,27–33}. Based on these key findings, metreleptin, the recombinant human leptin analog, has been adopted as the therapeutic of choice for the treatment of lipodystrophy and approved by the US Food and Drug Administration (FDA) in February 2014 for the treatment of metabolic abnormalities in patients with congenital generalized and acquired lipodystrophy³⁴. However, leptin does more than targeting the metabolic system. Leptin is a pleiotropic hormone which controls numerous organ systems and has been positively associated with hypertrophic cardiomyopathy, hypertension, and vascular inflammation in the context of obesity^{35,36}. Whether restoring leptin levels in lipodystrophic patients with metreleptin represents a cardiovascular risk remains unclear. The goal of the present manuscript is to review the clinical and basic science literature to provide a current description of the cardiovascular diseases developed by lipodystrophy patients and rodent models of lipodystrophy and discuss the potential cardiovascular consequences of supplementing lipodystrophy patients chronically with leptin.

Cardiovascular diseases associated with lipodystrophy

Cardiomyopathy, demonstrated by echocardiography and ECG, is a frequent finding in patients with both congenital and acquired forms of lipodystrophy, who develop similar cardiac abnormalities. A majority of patients with lipodystrophy presents hypertrophic cardiomyopathy as early as 6 months of age, as reported in a young girl with congenital generalized lipodystrophy due to seipin (*BSCL2*) mutation³⁷. Minimal numbers of patients with lipodystrophy have features of dilated cardiomyopathy. Classically, it is believed that congenital lipodystrophy patients with underlying *BSCL2* mutation have the highest prevalence of cardiomyopathy. Up to 80% of those affected have been reported to develop left ventricular hypertrophy with frequent abnormalities on ECGs resulting from long QT syndrome and a predisposition to tachyarrhythmias, including catecholaminergic polymorphic ventricular tachycardia and sudden cardiac death. Patients with underlying *AGPAT* mutation present a lower, but still high, prevalence (53%) of left ventricular hypertrophy. Lastly, patients with acquired generalized lipodystrophy have been reported to develop cardiac hypertrophy but of a significantly milder nature^{38,39}.

Cardiomyopathies and sudden cardiac arrest contribute to the high prevalence of death from cardiovascular causes and to the very early mortality of patients with lipodystrophy. Owing to the rarity of the disease and the paucity of patients, actual data on the cause of death in lipodystrophy patients remain scarce. Nevertheless, a recent study in 20 congenital lipodystrophy patients with *BSCL2* mutation reported a mean age of death of 27 years old, with death from cardiovascular causes representing the third cause of death after hepatic failure and respiratory infection^{16,40,41}.

The underlying etiology of the cardiac abnormalities in lipodystrophy remain unclear. Severe insulin resistance and hyperlipidemia, which are characteristic of lipodystrophy patients, may provide the context for the development of hypertrophic cardiomyopathy. However, hypertrophic cardiomyopathy is more frequently seen in patients with *BSCL2* mutation, who have overall milder metabolic abnormalities (including lower triglyceride levels and glycated hemoglobin) than in the *AGPAT* or acquired lipodystrophy groups³⁸. Hypertension, another major contributor to cardiomyopathy, affects between 30 and 50% of patients with lipodystrophy^{42,43}. However, whether patients with *BSCL2* mutation who have the highest prevalence of cardiomyopathy are also more prone to hypertension remains unknown. One can hope that future clinical studies investigating the effects of metreleptin on cardiomyopathy will help address the question of the respective contribution of insulin resistance and hyperlipidemia, as well as hypertension, to lipodystrophy-associated cardiomyopathy. Indeed, metreleptin, the human recombinant leptin analog recently approved for the treatment of metabolic disorders associated with lipodystrophy, has proven to be efficacious at restoring insulin sensitivity and lipids levels⁷ but failed to restore blood pressure in patients with lipodystrophy⁴². An improved cardiac function with metreleptin would support a role for

metabolic disorders in lipodystrophy-associated cardiomyopathy. Experimental studies in animal models of lipodystrophy represent an additional avenue for investigation of the underlying mechanisms.

Dyslipidemia and diabetes are leading causes of vascular disease and atherosclerosis. However, despite high prevalence of marked lipidemia and diabetes, only a few cases of atherosclerosis have been reported in lipodystrophy patients with either *BSCL2* or *AGPAT* mutations⁴⁰. The relatively young age of the patients at the time of the study or death may explain the low prevalence for an age-related disease. In opposition to patients with other forms of lipodystrophy, patients with familial partial lipodystrophy (FPLD) and notably females suffering from the Dunnigan-type exhibit a high prevalence of coronary artery disease most likely caused by a very severe hypertriglyceridemia⁴⁰. Although metreleptin treatment has proven to markedly reduce triglyceride levels in FPLD, it remains unknown whether it could reduce the incidence of atherosclerosis in these patients⁴⁴.

Together, these reports highlight the severity of the cardiovascular disorders developed by lipodystrophy patients and our lack of knowledge of their pathogenesis as well as stress our need for additional studies investigating their underlying mechanisms.

Table 1 summarizes the metabolic and cardiovascular alterations reported in patients with different forms of lipodystrophy.

Cardiovascular disease in mouse models of lipodystrophy

The rare aspect of the disease, its difficult diagnosis, and its consequent paucity in patients represent major limiting factors to the study of the etiology and pathological manifestations of lipodystrophy. Fortunately, several mouse models, which reproduce the metabolic and cardiovascular abnormalities observed in humans with lipodystrophy, have been developed and employed to better analyze the origins and consequences of this rare

syndrome^{45–47}. The following section and **Table 2** describe and discuss the phenotype of several of these models.

Constitutive deletion of *BSCL2*⁴⁸ and *Cav1*^{–/–} or selective deletion of peroxisome proliferator activated receptor γ (PPAR γ)^{50,51} and pro-renin receptor⁵² in adipocytes has been shown to reproduce the human congenital generalized lipodystrophy syndrome in mice. Each of these mouse models exhibit a near-complete absence of adipose tissue associated with impaired glucose tolerance and hyperlipidemia. Similarly, overexpression of the sterol regulatory element-binding protein-1c (SREBP-1c)^{47,53} and expression of the dominant negative A-ZIP/F-1 protein⁵⁴ in adipose tissue reproduce well the human lipodystrophy phenotype in terms of fat mass and distribution as well as metabolic alterations. This close proximity between the metabolic phenotype of these mouse models and of human patients makes these murine models the ideal tool to investigate the etiology of cardiovascular disease in lipodystrophy.

The seipin-deficient (*BSCL2*^{–/–}) mouse is the model that has been the most extensively studied for its cardiovascular phenotype. Several groups have observed that *BSCL2*^{–/–} mice, just like lipodystrophy patients³⁷, exhibit cardiac hypertrophy very early in life, as early as postnatal day 10⁵⁵. Cardiac hypertrophy persists throughout adulthood and progresses to cardiomyopathy with aging⁵⁵. Results gathered with independent lines of *BSCL2* knockout mice concur on the structural and hemodynamic alterations induced by lipodystrophy but diverge on the pathogenesis of the cardiac phenotype. Joubert *et al.*⁵⁶ reported no intramyocardial lipid accumulation or lipotoxic hallmarks but detected increased myocardial glucose uptake and O-GlycNAcylated protein in *BSCL2*^{–/–} hearts, in support of a cardiac glucose overload. Additional arguments in furtherance of an impaired cardiac glucose metabolism were provided by demonstrating that treatment with the hypoglycemic sodium glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin prevented the development of hypertrophic cardiomyopathy in *BSCL2*^{–/–} mice. Zhou *et al.*⁵⁵,

Table 1. Human lipodystrophy and their characteristics.

Human disease	Genetic changes	Function of gene	Metabolic Phenotype	CV phenotype	Ref
Berardinelli-Seip congenital lipodystrophy	Mutation in <i>AGPAT2</i> and <i>BSCL2</i>	Important for lipid droplet formation and adipocyte maturation	Enlarged and fatty liver, drastic reduction in fat mass, hyperinsulinemia, hyperglycemia, and hypertriglyceridemia	Cardiac hypertrophy, LV dysfunction, calcific aortic valve, and hypertension	37,38,43
Mutant PPAR γ	Heterozygous mutations in the ligand-binding domain of PPAR γ	Adipogenesis and adipocyte differentiation	Elevated glucose and insulin	Hypertension	57,58
Dunnigan type (FPLD2)	Mutations in <i>LMNA</i> encoding nuclear lamin A/C	Inhibits adipocyte differentiation	Insulin resistance	Hypertension and moderate LV dysfunction and dilation	38,59,60

AGPAT2, 1-acyl-sn-glycerol 3-phosphate O-acyltransferase 2; Bsc12, Berardinelli-Seip congenital lipodystrophy 2; C/EBP, CCAAT-enhancer-binding proteins; CV, cardiovascular; FPLD2, familial partial lipodystrophy type 2; LV, left ventricle; PPAR γ , peroxisome proliferator-activated receptor gamma; SREBP-1c, sterol regulatory element-binding protein 1.

Table 2. Mouse models of lipodystrophy and their characteristics.

Mouse model	Genetic manipulation	Function of gene	Metabolic phenotype	CV phenotype	Ref
Caveolin 1	Global deficiency	Role in lipid droplet formation by regulating lipids and phospholipid translocation across the plasma	Elevated TG and reduced leptin plasma levels	Vascular dysfunction, right ventricular hypertrophy, cardiomyopathy, and protected from atherosclerosis ⁶¹	49,62–64
AGPAT2	Global deficiency	Catalyzes the acylation of lysophosphatidic acid to phosphatidic acid	Hyperglycemia, elevated HbA1c, hyperinsulinemia, enlarged livers, and very low adiponectin and leptin levels	Not described	65–67
Bscl2/Seipin	Global	Important for lipid droplet formation and adipocyte maturation	Enlarged and fatty liver, drastic reduction in fat mass, plasma leptin, and adiponectin levels, hyperinsulinemia, and hyperglycemia	Cardiac hypertrophy, cardiac dysfunction, and endothelial dysfunction	45,48,56,68
Bscl2/Seipin	Adipocyte-specific deficiency	Important for lipid droplet formation and adipocyte maturation	Enlarged and fatty liver, drastic reduction in fat mass, plasma leptin, and adiponectin levels, hyperinsulinemia, and hyperglycemia	Not described	48
PPAR γ	Adipocyte-specific deficiency	Adipogenesis and adipocyte differentiation	Enlarged and fatty liver, reduced leptin, diabetes, and elevated TG	Not described	50,51
Pro-renin receptor	Adipocyte-specific deficiency	Receptor for pro-renin or renin	Hyperinsulinemia, enlarged liver and pancreas, and reduced leptin plasma levels	Hypertension	52,69
SREBP-1c	Adipocyte-specific overexpression	Lipid biosynthesis in animal cells	Hyperinsulinemia, hyperglycemia, insulin resistance, fatty liver, and reduced leptin	Not described	47,53
A-ZIP/F-1	Adipocyte-specific deficiency	ZIP/F prevents the DNA binding of B-ZIP transcription factors of both the C/EBP and Jun families	Hyperinsulinemia, hyperglycemia, elevated TG, and reduced leptin plasma levels	Vascular dysfunction and remodeling and hypertension	54,70,71

AGPAT2, 1-acyl-sn-glycerol 3-phosphate O-acyltransferase 2; Bscl2, Berardinelli-Seipin congenital lipodystrophy 2; C/EBP, CCAAT-enhancer-binding proteins; CV, cardiovascular; PPAR γ , peroxisome proliferator-activated receptor gamma; SREBP-1c, Sterol regulatory element-binding protein 1; TG, triglycerides.

on the other hand, identified an important link between hyperinsulinemia and organomegaly in lipodystrophic mice. They showed that activation of prohypertrophic insulin-like growth factor 1 receptor (IGF1R)-mediated PI3K/AKT signaling contributes to cardiac hypertrophy in *BSCL2*^{-/-} mice. They also identified a unique pattern of cardiac lipid remodeling with reduced

cardiac steatosis associated with adipose triglyceride lipase (ATGL) overexpression in hearts of *BSCL2*^{-/-} mice and showed that ATGL haploinsufficiency could reverse lipodystrophy, insulin resistance, and cardiac derangements. While these two studies depart on the underlying pathological mechanisms of hypertrophic cardiomyopathy in *BSCL2*^{-/-} mice, they strongly support a role for

metabolic alterations. Interestingly, using the exact same mouse as the mouse employed by Chen *et al.*⁴⁵ and Zhou *et al.*⁵⁵, our group recently reported that lipodystrophy impairs aortic endothelium-dependent relaxation by mechanisms independent of metabolic function. Indeed, we showed that restoration of glycemia via SGLT2 inhibition failed to restore endothelial function. However, we demonstrated that the absence of adipose tissue characteristic of lipodystrophy induced a reduction in systemic leptin levels which diminished endothelial leptin signaling and caused endothelial dysfunction via an overproduction of reactive oxygen species by endothelial NADPH oxidase 1 (Nox1)⁶⁸. Together, these observations further highlight the complexity of the disease and suggest that metabolic alterations are not the only cause of cardiovascular disease in lipodystrophy.

The *Cav1*^{-/-} mouse is another model that has been used to study lipodystrophy and also present cardiomyopathy^{49,62–64,72}. Differently from *BSCL2*^{-/-} mice, *Cav1*^{-/-} mice exhibit concentric left ventricular hypertrophy and dilated right ventricular hypertrophy. The discrepancy in the cardiac phenotype between *BSCL2*^{-/-} and *Cav1*^{-/-} might find its origin in the etiology of the cardiomyopathy. Indeed, as described above, metabolic disorders, notably insulin resistance and hyperglycemia, appear as the primary causes of cardiomyopathy in *BSCL2*^{-/-} mice. In opposition, in *Cav1*^{-/-} mice, cardiomyopathy was shown to be secondary to Cav1 deletion and pulmonary hypertension. Indeed, selective restoration of Cav1 expression in endothelial cells completely rescued pulmonary hypertension and cardiac hypertrophy in *Cav1*^{-/-} mice⁷³. Remarkably, *Cav1*^{-/-} mice are protected from atherosclerosis, again through mechanisms independent of lipodystrophy likely involving reduction in LDL infiltration into the artery wall, increased nitric oxide production, and reduction in the expression of leukocyte adhesion molecules⁶¹. Therefore, the *Cav1*^{-/-} mouse may be less relevant to the study of lipodystrophy and its cardiovascular consequences.

A key feature of lipodystrophy is dyslipidemia, notably hyperlipidemia which, added to insulin resistance and diabetes, places patients with lipodystrophy at a high risk for atherosclerotic cardiovascular disease^{74–79}. To investigate whether lipodystrophy predisposes to atherosclerosis, Wang *et al.*⁷⁴ crossed *BSCL2*^{-/-} with low-density lipoprotein receptor (*LDLR*^{-/-}) knockout mice, a mouse model of atherosclerosis. As observed in lipodystrophic patients⁴⁰, *LDLR*^{-/-} *BSCL2*^{-/-} mice present with accelerated atherosclerosis, as reflected by spontaneous plaque formation on chow diet and exacerbation of atherosclerotic lesions on atherogenic diet⁷⁴. The absence of adipocytes, which decreases the potential for adipose cholesterol clearance, most likely explains the extremely high rise in plasma cholesterol levels in *LDLR*^{-/-} *BSCL2*^{-/-} mice which itself predisposed lipodystrophic mice to atherosclerosis⁷⁴.

Lastly, mouse models of lipodystrophy, as do patients, present with hypertension^{27,43}. Experiments conducted in transgenic

A-ZIP/F-1 mice^{70,80} and adipose tissue pro-renin receptor-deficient mice⁵² revealed elevated systolic blood pressure associated with hyperactivation of the renin angiotensin system (RAS). Angiotensin-converting enzyme inhibition⁸¹ and angiotensin type 1 receptor blockade⁸⁰ restored blood pressure in these two mouse models of lipodystrophy, which further supports the contribution of RAS to the development of hypertension in mouse models of lipodystrophy and presents RAS blockade as a potential avenue for the treatment of cardiovascular disease associated with lipodystrophy. However, whether RAS overactivation is consecutive to metabolic alterations remains to be determined.

Metreleptin and lipodystrophy-associated cardiovascular disease

Following many successful trials, the FDA has approved leptin (metreleptin) for the treatment of non-HIV-related forms of generalized lipodystrophy. Leptin replacement therapy with metreleptin has, in many cases, reversed the metabolic complications, with improvements in glucose-insulin-lipid homeostasis and regression of fatty liver disease^{7,16,18,19,27–33}. An aspect of the treatment that remains ill-defined is whether metreleptin improves or alters cardiovascular function in lipodystrophic patients. Compelling basic science and clinical evidence indicate that excess leptin elevates blood pressure and impairs vascular function via sympatho-activation in males^{82–86} and aldosterone production in females^{82,87,88}. Therefore, concerns have been raised regarding the potential deleterious cardiovascular consequences of daily leptin injections. Recent results by Brown *et al.* partially dissipated these concerns by reporting that metreleptin did not elevate blood pressure in a relatively large population of lipodystrophic patients (107 patients)⁴². Based on their results, the authors concluded that there was a lack of contribution of leptin to the development of hypertension and a lack of translatability of the results obtained in murine models. However, the significant improvements in glycemia, insulin resistance, and liver and renal function associated with metreleptin treatment¹⁸ were not considered by the authors to reach their conclusions. Indeed, insulin resistance has been presented as a major risk factor for hypertension^{89,90}. Therefore, the significant improvement in the metabolic profile of the lipodystrophy patients on metreleptin most certainly compensated for the indisputable effects of leptin on sympathetic tone⁹¹. This may explain the lack of significant decreases in pressure in lipodystrophy patients on metreleptin. In addition, besides increasing sympathetic activity, leptin exerts vascular actions which could provide additional explanations for the lack of increase in blood pressure. Early work by the group of Lembo *et al.*, and supported by others, demonstrated that leptin not only relaxes blood vessels via NO-dependent mechanisms^{92,93} but also controls vascular integrity by protecting vessels from neointima formation, excess endothelin 1 production, and increasing PPARγ activity⁹⁴. Furthermore, recent results by our group show that leptin replacement therapy restores endothelium-dependent relaxation via direct activation of endothelial leptin receptor and reduction in Nox1-derived ROS

production, likely via PPAR γ -dependent mechanisms, in *BSCL2*^{-/-} mice⁵⁷. Taken together, these results further support the direct vascular effects of leptin and indicate that metreleptin treatment should improve vascular function in lipodystrophy patients.

Other potential concerns are the chronic effects of metreleptin on cardiac function and remodeling. Indeed, while compelling *in vitro* studies have shown that leptin promotes human and rodent cardiomyocyte hyperplasia^{95,96}, several clinical studies have established a positive correlation between leptin and left ventricular hypertrophy after adjustment for body mass index and present leptin as an independent predictor of incident heart failure⁹⁷. Conversely, elegant rescue experiments involving either selective restoration of leptin receptor expression in cardiomyocytes of leptin receptor-deficient mice (*db/db*) or restoration of leptin levels in leptin-deficient (*ob/ob*) mice report a decreased heart mass and reduction in left ventricular wall thickness in response to leptin, supportive of the cardiac protective effects of leptin. In addition, selective cardiac leptin receptor deficiency resulted in transient left ventricular dysfunction and dramatic reduction in ejection fraction, while cardiac-specific overexpression of leptin receptors normalized cardiac triglyceride levels and diastolic function in *db/db*⁹⁷. All together, these data derived from murine models support a beneficial role for leptin in cardiac function and metabolism (protection from lipotoxicity) but drastically contrast with the clinical studies. This further raises the question of the potential contribution of leptin deficiency to the cardiac disorders associated with lipodystrophy and of the effects of daily metreleptin injections on the severely impaired heart function of lipodystrophic patients. Additional studies are warranted to address these concerns.

Lastly, although not tested yet, one can reasonably speculate that metreleptin exerts protective effects against atherosclerosis. While insulin resistance, diabetes, and, more specifically, hyperlipidemia are leading risk factors for atherosclerosis, compelling evidence from relatively large (66 patients) studies have demonstrated that long-term treatment with metreleptin resulted in sustained improvements in hypertriglyceridemia, glycemic control, and liver volume which led to discontinuation of insulin, oral anti-diabetics, and lipid-lowering medications in more than 25% of patients on metreleptin¹⁸. Therefore, one can soundly anticipate that metreleptin will significantly reduce the risk for atherosclerosis in lipodystrophy patients through centrally orchestrated mechanisms reducing food intake but also through direct and local effects of leptin activating β -oxidation of fatty acids and preventing lipogenesis in the liver and skeletal muscles⁹⁸. Remarkably, another recent study reported that metreleptin treatment for 1 year reduced plasma levels of the proprotein convertase subtilisin/kexin type 9 (PCSK9), a key regulator of cholesterol metabolism, in humans with congenital

lipodystrophy⁹⁹. This provides an additional potential mechanism whereby metreleptin might prevent atherogenesis in lipodystrophy patients. However, the hypothesis that metreleptin protects from atherosclerosis remains to be tested. Less promising and beneficial evidence from animal studies further support this need for additional studies. Indeed, while leptin deficiency has been shown to protect apolipoprotein-E-deficient mice fed an atherogenic diet from the development of atherosclerosis lesions, exogenous leptin significantly increases atherosclerotic areas in apoE-deficient mice. In addition, leptin has been shown to promote the differentiation of macrophages towards a proinflammatory phenotype¹⁰⁰, which is another major contributor to atherosclerosis. It is therefore crucial to determine whether metreleptin prevents or exacerbates atherosclerogenesis in lipodystrophy patients.

Recent studies following patients for up to 3 years have reported that metreleptin is well tolerated in patients with lipodystrophy¹⁸. However, as with any other drug, metreleptin has been associated with a few side effects. Antimetroleptin antibodies with *in vitro* neutralizing activity, which could potentially reduce the drug's efficacy or even inhibit endogenous leptin activity¹⁰¹, have been shown to develop in most patients within 4–6 months but to decrease with continuous therapy. In addition, few patients under metreleptin treatment have been shown to develop T-cell lymphoma. However, whether metreleptin is truly a contributor requires further investigation, as patients with lipodystrophy appear to be at a higher risk for lymphoma than the general population, likely because of underlying autoimmunity¹⁰². Therefore, metreleptin-associated side effects may still deserve some attention.

Conclusion

In summary, while the current literature on lipodystrophy focuses mostly on the metabolic disorders associated with the syndrome, cardiovascular diseases, notably hypertension and cardiomyopathy (Figure 1), also represent a major health concern in patients with lipodystrophy and contribute to their very early mortality. Here, we speculated that the metreleptin regimen provided to lipodystrophy patients may improve cardiovascular function through its beneficial effects on glycemia, lipidemia, and liver function. We also stressed that metreleptin may affect cardiac and vascular function through direct control of cardiomyocyte and endothelial cell function and highlighted the need for studies investigating whether metreleptin improves or impairs the function of these two types of cells. We presented several mouse models of lipodystrophy which reproduce well the metabolic and cardiovascular phenotype of patients with lipodystrophy and represent the perfect avenue to investigate the direct effects of leptin on the cardiovascular system and dissipate any potential harmful effect.

Figure 1. Potential Mechanisms leading to cardiovascular disease in lipodystrophy. Lipodystrophy is associated with a drastic reduction in adiposity and leptin plasma levels, which lead to hyperglycemia, lipotoxicity, and decreased cellular leptin signaling. These changes have been associated with non-alcoholic fatty liver disease (NAFLD) endothelial dysfunction, hypertension, and cardiac diseases.

References

- Fiorenza CG, Chou SH, Mantzoros CS: **Lipodystrophy: pathophysiology and advances in treatment.** *Nat Rev Endocrinol.* 2011; 7(3): 137–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Yupanqui-Lozano H, Bastarrachea RA, Yupanqui-Velazco ME, *et al.*: **Congenital Leptin Deficiency and Leptin Gene Missense Mutation Found in Two Colombian Sisters with Severe Obesity.** *Genes (Basel).* 2019; 10(5): 342.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Metreleptin (Myalept): a leptin analog for generalized lipodystrophy. *Med Lett Drugs Ther.* 2015; 57(1460): 13–4.
[PubMed Abstract](#)
- Diker-Cohen T, Cochran E, Gordon P, *et al.*: **Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.** *J Clin Endocrinol Metab.* 2015; 100(5): 1802–10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Garg A: **Clinical review#: Lipodystrophies: genetic and acquired body fat disorders.** *J Clin Endocrinol Metab.* 2011; 96(11): 3313–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Hegele RA, Joy TR, Al-Attar SA, *et al.*: **Thematic review series: Adipocyte Biology. Lipodystrophies: windows on adipose biology and metabolism.** *J Lipid Res.* 2007; 48(7): 1433–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Oral EA, Simha V, Ruiz E, *et al.*: **Leptin-replacement therapy for lipodystrophy.** *N Engl J Med.* 2002; 346(8): 570–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Patni N, Garg A: **Congenital generalized lipodystrophies--new insights into metabolic dysfunction.** *Nat Rev Endocrinol.* 2015; 11(9): 522–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Magré J, Delépine M, Khallouf E, *et al.*: **Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13.** *Nat Genet.* 2001; 28(4): 365–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kim CA, Delépine M, Boutet E, *et al.*: **Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy.** *J Clin Endocrinol Metab.* 2008; 93(4): 1129–34.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Hayashi YK, Matsuda C, Ogawa M, *et al.*: **Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy.** *J Clin Invest.* 2009; 119(9): 2623–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Agarwal AK, Arioglu E, De Almeida S, *et al.*: **AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34.** *Nat Genet.* 2002; 31(1): 21–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Genschel J, Schmidt HH: **Mutations in the LMNA gene encoding lamin A/C.** *Hum Mutat.* 2000; 16(6): 451–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Chan JL, Lutz K, Cochran E, *et al.*: **Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.** *Endocr Pract.* 2011; 17(6): 922–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Goetzman ES, Tian L, Nagy TR, *et al.*: **HIV protease inhibitor ritonavir induces lipodystrophy in male mice.** *AIDS Res Hum Retroviruses.* 2003; 19(12): 1141–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Machado MV, Cortez-Pinto H: **Leptin in the treatment of lipodystrophy-associated nonalcoholic fatty liver disease: are we there already?** *Expert Rev Gastroenterol Hepatol.* 2013; 7(6): 513–5.
[PubMed Abstract](#) | [Publisher Full Text](#)

17. Akinci G, Akinci B: **Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy.** *Recent Pat Endocr Metab Immune Drug Discov.* 2015; 9(2): 74–8. [PubMed Abstract](#) | [Publisher Full Text](#)
18. **F** Brown RJ, Oral EA, Cochran E, *et al.*: **Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy.** *Endocrine.* 2018; 60(3): 479–489. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
19. Ebihara K, Kusakabe T, Hirata M, *et al.*: **Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.** *J Clin Endocrinol Metab.* 2007; 92(2): 532–41. [PubMed Abstract](#) | [Publisher Full Text](#)
20. Muniyappa R, Brown RJ, Mari A, *et al.*: **Effects of leptin replacement therapy on pancreatic β -cell function in patients with lipodystrophy.** *Diabetes Care.* 2014; 37(4): 1101–7. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. **F** Lima JG, Nobrega LHC, Lima NN, *et al.*: **Causes of death in patients with Berardinelli-Seip congenital generalized lipodystrophy.** *PLoS One.* 2018; 13(6): e0199052. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
22. McGuire MJ, Ishii M: **Leptin Dysfunction and Alzheimer's Disease: Evidence from Cellular, Animal, and Human Studies.** *Cell Mol Neurobiol.* 2016; 36(2): 203–17. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Pocai A, Morgan K, Buettner C, *et al.*: **Central leptin acutely reverses diet-induced hepatic insulin resistance.** *Diabetes.* 2005; 54(11): 3182–9. [PubMed Abstract](#) | [Publisher Full Text](#)
24. Haque MS, Minokoshi Y, Hamai M, *et al.*: **Role of the sympathetic nervous system and insulin in enhancing glucose uptake in peripheral tissues after intrahypothalamic injection of leptin in rats.** *Diabetes.* 1999; 48(9): 1706–12. [PubMed Abstract](#) | [Publisher Full Text](#)
25. Minokoshi Y, Haque MS, Shimazu T: **Microinjection of leptin into the ventromedial hypothalamus increases glucose uptake in peripheral tissues in rats.** *Diabetes.* 1999; 48(2): 287–91. [PubMed Abstract](#) | [Publisher Full Text](#)
26. Toda C, Shiuchi T, Lee S, *et al.*: **Distinct effects of leptin and a melanocortin receptor agonist injected into medial hypothalamic nuclei on glucose uptake in peripheral tissues.** *Diabetes.* 2009; 58(12): 2757–65. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. **F** Brown RJ, Meehan CA, Cochran E, *et al.*: **Effects of Metreleptin in Pediatric Patients With Lipodystrophy.** *J Clin Endocrinol Metab.* 2017; 102(5): 1511–1519. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
28. **F** Brown RJ, Valencia A, Startzell M, *et al.*: **Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.** *J Clin Invest.* 2018; 128(8): 3504–3516. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
29. Inui A: **Leptin-replacement therapy in lipodystrophy.** *N Engl J Med.* 2002; 346(25): 2009; author reply 2009–10. [PubMed Abstract](#) | [Publisher Full Text](#)
30. Javor ED, Cochran EK, Musso C, *et al.*: **Long-term efficacy of leptin replacement in patients with generalized lipodystrophy.** *Diabetes.* 2005; 54(7): 1994–2002. [PubMed Abstract](#) | [Publisher Full Text](#)
31. Mauvais-Jarvis F: **Leptin-replacement therapy in lipodystrophy.** *N Engl J Med.* 2002; 346(25): 2008; author reply 2009–10. [PubMed Abstract](#) | [Publisher Full Text](#)
32. Mulligan K, Khatami H, Schwarz JM, *et al.*: **The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipodystrophy and hypoleptinemia.** *J Clin Endocrinol Metab.* 2009; 94(4): 1137–44. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Wolfsdorf J, Sadeghi-Nejad A, Senior B: **Leptin-replacement therapy in lipodystrophy.** *N Engl J Med.* 2002; 346(25): 2008–9; author reply 2009–10. [PubMed Abstract](#) | [Publisher Full Text](#)
34. FDA: **Myalept FDA US FOOD & DRUG.** 2014; 2019.
35. Hall JE, do Carmo JM, da Silva AA, *et al.*: **Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms.** *Circ Res.* 2015; 116(6): 991–1006. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Faulkner JL, Belin de Chantemèle EJ: **Sex Differences in Mechanisms of Hypertension Associated With Obesity.** *Hypertension.* 2018; 71(1): 15–21. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Bhayana S, Siu VM, Joubert GI, *et al.*: **Cardiomyopathy in congenital complete lipodystrophy.** *Clin Genet.* 2002; 61(4): 283–7. [PubMed Abstract](#) | [Publisher Full Text](#)
38. Lupsa BC, Sachdev V, Lungu AO, *et al.*: **Cardiomyopathy in congenital and acquired generalized lipodystrophy: a clinical assessment.** *Medicine (Baltimore).* 2010; 89(4): 245–50. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Sanon VP, Handelsman Y, Pham SV, *et al.*: **Cardiac Manifestations of Congenital Generalized Lipodystrophy.** *Clin Diabetes.* 2016; 34(4): 181–186. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. **F** Hussain I, Patni N, Garg A: **Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease.** *Pathology.* 2019; 51(2): 202–212. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
41. Prieur X, Le May C, Magré J, *et al.*: **Congenital lipodystrophies and dyslipidemias.** *Curr Atheroscler Rep.* 2014; 16(9): 437. [PubMed Abstract](#) | [Publisher Full Text](#)
42. Brown RJ, Meehan CA, Gorden P: **Leptin Does Not Mediate Hypertension Associated With Human Obesity.** *Cell.* 2015; 162(3): 465–6. [PubMed Abstract](#) | [Publisher Full Text](#)
43. Rêgo AG, Mesquita ET, Faria CA, *et al.*: **[Cardiometabolic abnormalities in patients with Berardinelli-Seip syndrome].** *Arq Bras Cardiol.* 2010; 94(1): 109–18. [PubMed Abstract](#) | [Publisher Full Text](#)
44. Rochford JJ: **Mouse models of lipodystrophy and their significance in understanding fat regulation.** *Curr Top Dev Biol.* 2014; 109: 53–96. [PubMed Abstract](#) | [Publisher Full Text](#)
45. Chen W, Chang B, Saha P, *et al.*: **Berardinelli-seip congenital lipodystrophy 2/seipin is a cell-autonomous regulator of lipolysis essential for adipocyte differentiation.** *Mol Cell Biol.* 2012; 32(6): 1099–111. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Asterholm IW, Halberg N, Scherer PE: **Mouse Models of Lipodystrophy Key reagents for the understanding of the metabolic syndrome.** *Drug Discov Today Dis Models.* 2007; 4(1): 17–24. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Shimomura I, Hammer RE, Ikemoto S, *et al.*: **Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy.** *Nature.* 1999; 401(6748): 73–6. [PubMed Abstract](#) | [Publisher Full Text](#)
48. Liu L, Jiang Q, Wang X, *et al.*: **Adipose-specific knockout of SEIPIN/BSCL2 results in progressive lipodystrophy.** *Diabetes.* 2014; 63(7): 2320–31. [PubMed Abstract](#) | [Publisher Full Text](#)
49. Razani B, Combs TP, Wang XB, *et al.*: **Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities.** *J Biol Chem.* 2002; 277(10): 8635–47. [PubMed Abstract](#) | [Publisher Full Text](#)
50. Wang F, Mullican SE, DiSpirito JR, *et al.*: **Lipoatrophy and severe metabolic disturbance in mice with fat-specific deletion of PPAR γ .** *Proc Natl Acad Sci U S A.* 2013; 110(46): 18656–61. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
51. He W, Barak Y, Hevener A, *et al.*: **Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle.** *Proc Natl Acad Sci U S A.* 2003; 100(26): 15712–7. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
52. Wu CH, Mohammadmoradi S, Thompson J, *et al.*: **Adipocyte (Pro)Renin-Receptor Deficiency Induces Lipodystrophy, Liver Steatosis and Increases Blood Pressure in Male Mice.** *Hypertension.* 2016; 68(1): 213–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
53. Shimomura I, Hammer RE, Richardson JA, *et al.*: **Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: Model for congenital generalized lipodystrophy.** *Genes Dev.* 1998; 12(20): 3182–94. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
54. Moitra J, Mason MM, Olive M, *et al.*: **Life without white fat: A transgenic mouse.** *Genes Dev.* 1998; 12(20): 3168–81. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
55. **F** Zhou H, Lei X, Yan Y, *et al.*: **Targeting ATGL to rescue BSCL2 lipodystrophy and its associated cardiomyopathy.** *JCI Insight.* 2019; 5: pii: 129781. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
56. Joubert M, Jagu B, Montaigne D, *et al.*: **The SGLT2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model.** *Diabetes.* 2017; 9(2): 171. [Publisher Full Text](#)
57. Barroso I, Gurnell M, Crowley VE, *et al.*: **Dominant negative mutations in human PPAR γ associated with severe insulin resistance, diabetes mellitus and hypertension.** *Nature.* 1999; 402(6764): 880–3. [PubMed Abstract](#) | [Publisher Full Text](#)
58. Auclair M, Vigouroux C, Boccara F, *et al.*: **Peroxisome proliferator-activated receptor- γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system.** *Arterioscler Thromb Vasc Biol.* 2013; 33(4): 829–38. [PubMed Abstract](#) | [Publisher Full Text](#)
59. **F** Boguslavsky RL, Stewart CL, Worman HJ: **Nuclear lamin A inhibits adipocyte differentiation: Implications for Dunnigan-type familial partial lipodystrophy.** *Hum Mol Genet.* 2006; 15(4): 653–63. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
60. Hegele RA, Leff T: **Unbuckling lipodystrophy from insulin resistance and hypertension.** *J Clin Invest.* 2004; 114(2): 163–5. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
61. Fernández-Hernando C, Yu J, Suárez Y, *et al.*: **Genetic evidence supporting a critical role of endothelial caveolin-1 during the progression of atherosclerosis.** *Cell Metab.* 2009; 10(1): 48–54. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
62. **F** Drab M, Verkade P, Elger M, *et al.*: **Loss of caveolae, vascular dysfunction,**

- and pulmonary defects in caveolin-1 gene-disrupted mice. *Science*. 2001; 293(5539): 2449–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
63. Razani B, Engelman JA, Wang XB, *et al.*: Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. *J Biol Chem*. 2001; 276(41): 38121–38.
[PubMed Abstract](#) | [Publisher Full Text](#)
 64. Zhao YY, Liu Y, Stan RV, *et al.*: Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. *Proc Natl Acad Sci U S A*. 2002; 99(17): 11375–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 65. Vogel P, Read R, Hansen G, *et al.*: Pathology of congenital generalized lipodystrophy in *Agpat2*^{-/-} mice. *Vet Pathol*. 2011; 48(3): 642–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
 66. Cautivo KM, Lizama CO, Tapia PJ, *et al.*: AGPAT2 is essential for postnatal development and maintenance of white and brown adipose tissue. *Mol Metab*. 2016; 5(7): 491–505.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 67. Fernández-Galilea M, Tapia P, Cautivo K, *et al.*: AGPAT2 deficiency impairs adipogenic differentiation in primary cultured preadipocytes in a non-autophagy or apoptosis dependent mechanism. *Biochem Biophys Res Commun*. 2015; 467(1): 39–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
 68. Bruder-Nascimento T, Faulkner JL, Haigh S, *et al.*: Leptin restores endothelial function via endothelial PPAR γ -Nox1 mediated mechanisms in a mouse model of congenital generalized lipodystrophy. *Hypertension*. In press.
 69. Nguyen G, Muller DN: The biology of the (pro)renin receptor. *J Am Soc Nephrol*. 2010; 21(1): 18–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
 70. Takemori K, Gao YJ, Ding L, *et al.*: Elevated blood pressure in transgenic lipotrophic mice and altered vascular function. *Hypertension*. 2007; 49(2): 365–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
 71. Kim JK, Gavrilova O, Chen Y, *et al.*: Mechanism of insulin resistance in A-ZIPF-1 fatless mice. *J Biol Chem*. 2000; 275(12): 8456–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
 72. Pavlides S, Gutierrez-Pajares JL, Danilo C, *et al.*: Atherosclerosis, caveolae and caveolin-1. *Adv Exp Med Biol*. 2012; 729: 127–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
 73. Murata T, Lin MI, Huang Y, *et al.*: Reexpression of caveolin-1 in endothelium rescues the vascular, cardiac, and pulmonary defects in global caveolin-1 knockout mice. *J Exp Med*. 2007; 204(10): 2373–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 74. Wang M, Gao M, Liao J, *et al.*: Adipose tissue deficiency results in severe hyperlipidemia and atherosclerosis in the low-density lipoprotein receptor knockout mice. *Biochim Biophys Acta*. 2016; 1861(1): 410–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 75. Cipriani S, Francisci D, Mencarelli A, *et al.*: Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. *Circulation*. 2013; 127(21): 2114–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
 76. Jiang B, Khandelwal AR, Rogers LK, *et al.*: Antiretrovirals induce endothelial dysfunction via an oxidant-dependent pathway and promote neointimal hyperplasia. *Toxicol Sci*. 2010; 117(2): 524–36.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 77. Jones KL, Maguire JJ, Davenport AP: Chemokine receptor CCR5: From AIDS to atherosclerosis. *Br J Pharmacol*. 2011; 162(7): 1453–69.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 78. Stein JH, Klein MA, Bellehumeur JL, *et al.*: Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. *Circulation*. 2001; 104(3): 257–62.
[PubMed Abstract](#) | [Publisher Full Text](#)
 79. Tawakol A, Lo J, Zanni MV, *et al.*: Increased arterial inflammation relates to high-risk coronary plaque morphology in HIV-infected patients. *J Acquir Immune Defic Syndr*. 2014; 66(2): 164–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 80. Lamounier-Zepter V, Bornstein SR, Kunes J, *et al.*: Adrenocortical changes and arterial hypertension in lipotrophic A-ZIPF-1 mice. *Mol Cell Endocrinol*. 2008; 280(1–2): 39–46.
[PubMed Abstract](#) | [Publisher Full Text](#)
 81. Gatineau E, Cohn DM, Poglitsch M, *et al.*: Losartan prevents the elevation of blood pressure in adipose-PRR deficient female mice while elevated circulating sPRR activates the renin-angiotensin system. *Am J Physiol Heart Circ Physiol*. 2019; 316(3): H506–H515.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 82. Belin de Chantemèle EJ: Sex Differences in Leptin Control of Cardiovascular Function in Health and Metabolic Diseases. *Adv Exp Med Biol*. 2017; 1043: 87–111.
[PubMed Abstract](#) | [Publisher Full Text](#)
 83. Belin de Chantemèle EJ, Mintz JD, Rainey WE, *et al.*: Impact of leptin-mediated sympatho-activation on cardiovascular function in obese mice. *Hypertension*. 2011; 58(2): 271–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 84. Belin de Chantemèle EJ, Muta K, Mintz J, *et al.*: Protein tyrosine phosphatase 1B, a major regulator of leptin-mediated control of cardiovascular function. *Circulation*. 2009; 120(9): 753–63.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 85. Bruder-Nascimento T, Butler BR, Herren DJ, *et al.*: Deletion of protein tyrosine phosphatase 1b in proopiomelanocortin neurons reduces neurogenic control of blood pressure and protects mice from leptin- and sympatho-mediated hypertension. *Pharmacol Res*. 2015; 102: 235–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
 86. Mark AL, Shaffer RA, Correia ML, *et al.*: Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow obese mice. *J Hypertens*. 1999; 17(12 Pt 2): 1949–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
 87. Huby AC, Antonova G, Groenendyk J, *et al.*: Adipocyte-Derived Hormone Leptin Is a Direct Regulator of Aldosterone Secretion, Which Promotes Endothelial Dysfunction and Cardiac Fibrosis. *Circulation*. 2015; 132(22): 2134–45.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 88. Huby AC, Otvos L, Belin de Chantemèle EJ: Leptin Induces Hypertension and Endothelial Dysfunction via Aldosterone-Dependent Mechanisms in Obese Female Mice. *Hypertension*. 2016; 67(5): 1020–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 89. Saad MF, Rewers M, Selby J, *et al.*: Insulin resistance and hypertension: the Insulin Resistance Atherosclerosis study. *Hypertension*. 2004; 43(6): 1324–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
 90. Arnlov J, Pencina MJ, Nam BH, *et al.*: Relations of insulin sensitivity to longitudinal blood pressure tracking: Variations with baseline age, body mass index, and blood pressure. *Circulation*. 2005; 112(12): 1719–27.
[PubMed Abstract](#) | [Publisher Full Text](#)
 91. Rahmouni K, Haynes WG, Mark AL: Cardiovascular and sympathetic effects of leptin. *Curr Hypertens Rep*. 2002; 4(2): 119–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
 92. Vecchione C, Maffei A, Colella S, *et al.*: Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. *Diabetes*. 2002; 51(1): 168–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
 93. Benkhoff S, Loot AE, Pierson I, *et al.*: Leptin potentiates endothelium-dependent relaxation by inducing endothelial expression of neuronal NO synthase. *Arterioscler Thromb Vasc Biol*. 2012; 32(7): 1605–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
 94. Hubert A, Bochenek ML, Schütz E, *et al.*: Selective Deletion of Leptin Signaling in Endothelial Cells Enhances Neointima Formation and Phenocopies the Vascular Effects of Diet-Induced Obesity in Mice. *Arterioscler Thromb Vasc Biol*. 2017; 37(9): 1683–97.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 95. Rajapurohitam V, Gan XT, Kirshenbaum LA, *et al.*: The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. *Circ Res*. 2003; 93(4): 277–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 96. Paolisso G, Tagliamonte MR, Galderisi M, *et al.*: Plasma leptin concentration, insulin sensitivity, and 24-hour ambulatory blood pressure and left ventricular geometry. *Am J Hypertens*. 2001; 14(2): 114–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
 97. Hall ME, Harmancey R, Stec DE: Lean heart: Role of leptin in cardiac hypertrophy and metabolism. *World J Cardiol*. 2015; 7(9): 511–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 98. Stern JH, Rutkowski JM, Scherer PE: Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis through Adipose Tissue Crosstalk. *Cell Metab*. 2016; 23(5): 770–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 99. Vattier C, Arnaud L, Prieur X, *et al.*: One-year metreleptin therapy decreases PCSK9 serum levels in diabetic patients with monogenic lipodystrophy syndromes. *Diabetes Metab*. 2017; 43(3): 275–279.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 100. Gainsford T, Willson TA, Metcalf D, *et al.*: Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. *Proc Natl Acad Sci U S A*. 1996; 93(25): 14564–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 101. Chan JL, Koda J, Heilig JS, *et al.*: Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy. *Clin Endocrinol (Oxf)*. 2016; 85(1): 137–49.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 102. Ltd WAP: Myalepta (metreleptin) 3, 5.8 and 11.3 mg powder for solution for injection: EU summary of product characteristics. Windsor: Aegerion Pharmaceuticals Ltd. 2018.
[Reference Source](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Xavier Prieur**

L'Institut du Thorax, INSERM, CNRS, Université de Nantes, Nantes, France

Competing Interests: No competing interests were disclosed.

2. **Frederique Yiannikouris**

Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, USA

Competing Interests: No competing interests were disclosed.

3. **Jussara do Carmo**

Department of Physiology and Biophysics, University of Mississippi Medical Center, Mississippi, USA

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research